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The paper discusses the results of a research on physicochemical and biochemical properties of the Keplerate-type molybdenum-based nanocluster
polyoxometalates (POMs), which show promise in the field of biomedicine as a means of targeted drug delivery, including the transport to immune
privileged organs. POMs can be considered as components of releasing systems, including the long-acting ones with feedback (for controlling the
drug active component release rate). POMs are promising drugs for the treatment of anemia. Also, the paper deals with the results of studies of
POM effect on living systems at the molecular and cellular levels, at that of individual organs, and on the organism as a whole. The mechanism
and kinetics of POM destruction and possibilities of stabilization, the oscillatory phenomena manifestation, the formation of POM conjugates with
bioactive substances which can be released during the destruction of POM, with polymer components, and with indicator fluorescent dyes, as well
as forecasts for further research, are considered.
Keywords: Keplerate-type nanocluster polyoxomolybdates, physicochemical and biochemical properties, impact on living systems, means of
targeted delivery, releasing systems, prolonged action.
Received: 27 March 2020
Revised: 14 July 2020, 19 January 2021
Contents
1. Introduction
1.1. Nanoscale components of targeted drug delivery systems.
1.2. Nanocluster polyoxometalates (POMs).
2. Investigation of the effect of Keplerate-type POMs on living systems at the level of the organism,
of individual organs, and at the molecular-cellular level.
2.1. Study of POMs accumulation characteristics and toxicity.
2.2. POMs impact at the cellular-molecular level.
3. Association of POMs with bioactive substances and polymers.
4. POMs destruction processes and their stabilization.




1.1. Nanoscale components of targeted drug delivery systems
The targeted delivery of drugs can employ nanostructured systems that differ in terms of the nature of compo-
nents and design, to which, for instance, liposomal systems belong [1–13]. Some natural aspects can impede the
use of liposomal agents. These aspects include the active capturing of liposomes by macrophages, which results
in the limited possibility of drug delivery to some organs and tissues. The capturing also significantly reduces the
time of drugs circulation in the organism, thus leading to the liposome membrane degradation under the influence of
lipoproteins. In addition, the manufacturing of liposomal products employs rather sophisticated technologies. Various
inorganic nanoscale objects are considered as components of targeted drug delivery systems; these include metal, ox-
ide or complex oxide objects, and some other types of nanoparticles [14–25], as well as carbon clusters (fullerenes,
nanotubes, graphene, and nanodiamonds) [26–59]. These objects can be used, for instance, as shells or cores of
nanocapsules, providing the release of drugs, for example, under local electromagnetic influence. They can play the
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role of carriers of bioactive substances in surface functionalization [44–46, 48, 49, 51–56], or when the porous struc-
ture of nanoparticles and clusters is used, including non-magnetic and magnetic systems for delivery, therapy [57–83]
and diagnostics [60–68]. The use of carbon clusters and inorganic nanoparticles is associated with the problem of
removing such materials from the body after they have performed their function, in order to reduce the xenobiotics
load.
Nanocluster polyoxometalates (POMs) can be produced and characterized in terms of composition and structure
using fairly simple and proven techniques. Representatives of this class of compounds, in particular molybdenum-
containing ones, do not pose a danger to a living organism and are practically non-toxic. They do not accumulate in
the body for long, because, for instance, they are capable of gradual decomposition into decay products, which are
assimilated as microelements and further evacuated in the course of natural metabolism. For these reasons, POMs are
considered as promising materials for targeted delivery of drugs, of long-acting therapeutic agents, including those
with feedback for controlling the drug release rate. Also, the advantages of POMs include their solubility in aqueous
media and the charge of polyanions, which provides the possibility of iontophoretic delivery. The present review
briefly discusses the biochemical properties of the most promising POMs, their ability to associate with biologically
active substances, as well as issues related to the processes of POM destruction and stabilization as a key aspects in
terms of biomedical application.
1.2. Nanocluster polyoxometalates (POMs)
Variously composed and structured POMs, which include both hetero- and isopoly compounds, have found a
wide application as catalytic systems, components of hybrid structures, supramolecular assemblies, etc. [84–87]. New
types of molybdenum-containing nanocluster polyoxometalates with toroidal [88–91] and fullerene-like structures
(Keplerates) containing subnanometer-sized windows and pores [92,93] (Fig. 1) became known at the turn of the past
and present centuries due to studies carried out at the Bielefeld University (Bielefeld, Germany) under the guidance
of Prof. A. Müller, whose laboratory synthesized these compounds and confirmed their structure. In comparison with
other nanosized particles, such water-soluble clusters have a high ionic charge and are capable of gradual degradation.
The discovery of such POMs was, apparently, one of those cases, which are far from rare in the history of science, when
such POMs had been most likely obtained in earlier experiments, but the researchers were unaware of their unique
structure, which was later deciphered and purposefully reproduced. The POM structure was primarily characterized
by single crystal X-ray structure analysis. The everyday scientific practice employs for this purpose reliable and more
rapid spectroscopic methods (e.g., IR, Raman, NMR spectroscopy) [94]. The obtaining of giant POM clusters was also
confirmed by mass spectrometry (MALDI method) [95]. Among the merits of Prof. Müller’s group is the creation of
fairly simple and reproducible methods for obtaining POM [93] with a specified structure and composition. In addition
to the above-mentioned, basket-like molybdenum-containing POMs [96], with a structure derived from Keplerates, as
well as giant clusters named by their creators “nano hedgehog”, “blue lemon” [97, 98] were also obtained.
The structure of these POMs is based on such structural blocks (coordination oxygen polyhedra surrounding mul-
ticharged metal cations) such as octahedra, pentagonal bipyramids, which are connected to each other by vertices or
edges. In particular, Mo2 dimolybdenum bridges, Mo6 and Mo11 blocks should be attributed to basic structural ele-
ments. The symmetry of the latter (C5 or Cs point group) determines the shape of the resulting nanocluster (Keplerate
or toroid, respectively). The structure of a POM is stabilized, as a rule, by the organic or inorganic acid residues and
water molecules. POMs contain a significant number of molecules of both constitutional and intracluster water. The
latter also occupy the internal cavity of Keplerates in the normal state and can exchange with molecules of other sub-
stances through the pores. POM synthesis proceeds in the self-assembly mode under conditions of a specified medium
acidity and in the presence of a reducing agent, since, for instance, the basic structure of Mo132 Keplerate (Fig. 1)




There is a possibility to use the basic structure of a POM and substitute ions in it. For instance, the isostructural
substitution of Mo(V) with ferric ions leads to the formation of a Mo72Fe30 Keplerate [99] (Fig. 2):
[Mo72Fe30O252(CH3COO)12{Mo2O7(H2O)}2{H2Mo2O8(H2O)}(H2O)91]∼150H2O.
The POMs isolated from the concentrated stock solution are mainly crystalline substances, which may include
a fraction of the material in an amorphous state [94]. Upon subsequent dissolution in water, POMs dissociate into
Keplerate polyanions and cations (ammonium, sodium and potassium), or do it as a weak acid (Mo72Fe30). The
crystallographic size of a Mo132 ion is 2.9 nm (Mo72Fe30 is 2.5 nm), while the hydrated Mo132 ion in a solution
has a size of 3.2 nm. The charge of polyanions depends on the acidity and environment, and can reach −42 and
−22 [93, 100] for Mo132 and Mo72Fe30, respectively.
The POMs capable, in principle, of changing the energy state of molecules included in their cavity, are considered
promising catalytic materials in reactions of fine organic synthesis, membrane technologies, and sensorics [101–113].
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FIG. 1. Structure of Mo132 polyoxometalate. The red polyhedron (No. 1) marks the pentagonal
MoO7 bipyramid, linked by common edges with five MoO6 octahedra (blue, No. 2) – this is the
so-called Mo6 structural unit; Highlighted in green (No. 3) are MoV O6 polyhedra, which are part of
Mo2 dimolybdenum bridges
FIG. 2. Structure of Mo72Fe30 polyoxometalate. Iron-coordinated oxygen polyhedra are marked in
yellow (No. 1 is MoO7; 2 is MoO6; 3 is FeO6)
At the same time, such compounds are also of interest for the biomedical industry (Scheme 1). On the one hand, they
can be interesting as individual drugs, because molybdenum and iron are widely known to be used in vitamin and min-
eral supplements as microelements involved in a number of enzymatic processes of importance for the organism [114].
In addition, it was shown that simpler molybdenum-containing POMs can be used in chemotherapy [115,116]. On the
other hand, the initially predicted possibility of the formation of POM conjugates with bioactive substances, drugs,
and metal cations using intra- and extrasphere interactions, the possibility of their transport (including iontophoretic)
in the body, adds relevance to the studies of POM in the field of targeted drug delivery and diagnostics [117–131].
These prospects may relate, inter alia, to immunomodulatory and antiviral agents. Important aspects of iontophoretic
transport include the potential ability to deliver drugs to lesion areas and body tissues with low degree of vasculariza-
tion. The very first experimental results showed that these ideas are promising. The low toxicity of Keplerate POMs
for the warm-blooded animals, in particular of the iron-containing compounds, has been established on the basis of
a set of data [132–137]. When studying the acute and subacute effects of Mo72Fe30 on rats, no significant negative
changes in internal organs were revealed. The animal organism is able to adapt to the action of the named POM,
which is confirmed by the absence of a pronounced autoimmune reaction of lymphocytes to hepatocytes during the
intramuscular administration of a Mo72Fe30 preparation in the form of an aqueous solution. There is no long-term and
substantial accumulation of POMs and their components in the body (various organs and tissues), as they are excreted
by metabolism. This occurs, inter alia, due to the POM degradation into simpler components [106,137]. The issues of
POM toxicity are discussed in more detail below. At the same time, in the case of iontophoretic administration, it is
possible to create a temporary Mo72Fe30 depot localized, for example, in the skin and partly in the subcutaneous fatty
tissue, which ensures a prolonged action of POM and its conjugates. In general, the present review is devoted to the
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consideration of specific properties and behavior of POMs, as well as to generalization of the results obtained by its
authors.
2. Investigation of the effect of Keplerate-type POMs on living systems at the level of the organism, of
individual organs, and at the molecular-cellular level
2.1. Study of POMs accumulation characteristics and toxicity
The chosen and studied1 POMs Mo132 and Mo72Fe30 exhibited both similar and different behavior due to their
different composition. While the first of them contains Mo(V) in addition to Mo(VI), the second one includes both
molybdenum and iron in the highest oxidation states, which makes it promising in terms of low toxicity (no lethality
found in animals). The accumulation of Mo132 [136] was studied by injecting it into the gastrocnemius muscle of
rats at a concentration of 1.5·10−4 mol/L daily for a month. A single dose of POM amounting to 0.15 mg/100 g
of the body weight, corresponded to the upper limit of the normal daily intake of molybdenum and to the supposed
therapeutic dose. Intact animals served as the control. The absence of the drug and its components accumulation in
the liver and bones was established. A sharp decrease in the content of molybdenum in the kidneys was found, the
cause of which is, apparently, the excretion of the excessive amount of this element via the urinary tract. Experiments
with the Mo72Fe30 polyoxometalate [132,133,137] administered at the same dosage, made it possible to establish for
this POM the absence of accumulation of molybdenum in the liver, kidneys, bones, and skin of animals, including its
hairy part and subcutaneous fatty tissue, since the average values of molybdenum content in the experimental samples
after the termination of the procedures did not differ significantly from those in the intact animals.
1The results of studies of the effect of Keplerate POMs on the animal subject, in particular, the data on transport, accumulation characteristics
and toxicity were obtained on outbred rats of both sexes, weighing 200–230 g, kept on the usual diet of the vivarium. The keeping conditions
and handling of the animals used in the experiment were in accordance with the principles formulated in Directive 2010/63/EU of the European
Parliament and of the European Council of 22 September 2010 on the protection of animals used for scientific purposes (Official Journal of the
European Union, 2010). European Parliament, Council, Directive 2010/63/EU of the European Parliament and of the Council of 22 September
2010 on the Protection of Animals Used for Scientific Purposes. Off. J. Eur. Union., 2010, 53, P. 33–79. doi:10.3000/17252555.L 2010.276.eng.
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The histological analysis [132,137] of animal organs [138] and the results of hematologic studies [134] indicated
a relatively higher toxicity of Mo132 as compared to Mo72Fe30. Signs of hepatocyte damage were observed for Mo132.
However, the characteristic signs of intensified liver regeneration processes were obviously observed. The histologic
analysis of kidney sections from the experimental group of animals after administration of Mo72Fe30 showed that the
structural changes in the organ were minimal. It should be stressed that a weaker toxic effect of iron-molybdenum
POMs [133, 139] was confirmed by the analysis of such biochemical parameters [140] characterizing the state of
various organs, as aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, alpha
amylase, urea, and the total protein.
An analysis of peripheral blood parameters [138, 140] of animals allowed one to draw the conclusion that there
was no anemia [141] in the group of animals that got Mo132 injections, since no significant difference was found in the
number of erythrocytes, concentration of hemoglobin, the content and concentration of hemoglobin in erythrocytes
in the experimental and intact rats. The total leukocytes in animals that got Mo132 injections also did not increase,
which indicates the absence of a systemic inflammatory process. The total leukocytes did not significantly increase in
the animals within 30 days after Mo72Fe30 injections, and the leukocyte formula remained almost unchanged, which
indicates the absence of inflammation at the organismal level.
An analysis of red blood parameters in rats injected with Mo72Fe30 yielded a conclusion that there was no ane-
mia – a sign characteristic of many chronic intoxications, since the content of hemoglobin in erythrocytes of exper-
imental rats did not decrease, but increased, on the contrary [108, 139, 142]. Moreover, the experimentally revealed
effect of rapid recovery of the hemoglobin level in animals after modeling the post-hemorrhagic anemia [141] is in-
teresting from the point of view of the possible use of POMs in treatment and prevention of iron deficiency anemia,
which is confirmed by a patent [142]. The presence of molybdenum in the preparation does not prevent an increase
in its effectiveness; besides, molybdenum is effectively removed from the body. Given its lower toxicity, Mo72Fe30
was subjected to additional studies, in particular, of acute and subacute toxicity [133]. In order to further study the
pathways of possible toxic action of POM [133], three methods of Keplerate administration were chosen, that is, the
intramuscular, intraperitoneal, and intragastric. The intragastric (1 day) method of administration allowed a significant
increase in the POM dose by using not only a POM solution, as in other methods, but also a suspension (concentration
of 60 mg/ml). The introduction of the maximum possible dose of POM by the intragastric method was not accompa-
nied by lethality, therefore, the conclusion about low toxicity of the tested compound was confirmed, especially since
the amount of POM was 200 times higher than the estimated therapeutic dose of 0.15 mg/100 g.
The blood plasma of rats in all experimental groups [133] showed no increase in the activity of alkaline phos-
phatase, which is one of the indicators of cholestasis(impaired bile secretion). This fact indicated that the bile-
producing function of hepatocytes was preserved after both short and long-term administration of POM. Alkaline
phosphatase is also a specific enzyme of osteoblasts, it is involved in mineralization, and the activity of this enzyme
is an indicator of changes in the rate of mineral components remodeling in the bone tissue. Molybdates are known
of being able to be capable of reducing the activity of phosphatases, probably through the interaction of molybdenum
with the cysteine thiol groups and histidine imidazole groups located in the active sites of enzymes [138, 140]. The
groups of animals with single intramuscular, intraperitoneal, and intragastric administration of Mo72Fe30 have shown
a relatively small (within 20–25%), but significant decrease in alkaline phosphatase activity [133], possibly due to
the inhibitory effect of molybdenum. Just a short-term, 1 day-long, decrease in the activity of alkaline phosphatase
eliminates the risk of osteoporosis development after a single administration of Keplerates.
When comparing the average values of other indicators in groups of animals with acute administration of POM
(alpha-amylase activity, total protein and creatinine content in blood plasma), no significant differences with those
of intact rats were found, which evidences the absence of pronounced changes in the kidneys, liver, and pancreas of
animals in these groups [133]. The group with subacute POM administration showed no significant deviations of all
the studied biochemical indicators from the norm, which suggested the absence of cytolysis and damage to the liver,
kidneys, myocardium, pancreas, and bone tissue after a long (30 days) daily POM administration.
It is important to note that after POM administration by all the studied methods, a significant increase in the
content of molybdenum in the blood was recorded [133] after a single POM load. The amount of molybdenum
found in the blood 1 day after the administration of Keplerate POMs was proportional to the amount of the injected
nanomaterial. A significant decrease in the level of molybdenum in the blood after 1 day compared to the content
of the microelement one hour after intramuscular injection, as well as the normalization of the indicator after daily
injections of POM within 30 days, was consistent with previously obtained data on the absence of molybdenum
accumulation [132, 137, 141]. The absence of molybdenum accumulation [133] in the liver, kidneys, skin, and bone
tissue [138] is probably associated with the decomposition and accelerated excretion of the elements constituting POM,
which contributes to the normalization of the studied parameters (glucose, aminotransferase, and alkaline phosphatase
values) [138] by day 30, a change of which was recorded upon a single injection of POM.
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2.2. POMs impact at the cellular-molecular level
Further investigations of Mo72Fe30 were aimed at studying its effect at the cellular and molecular level, since the
use of Mo72Fe30 as a means of targeted delivery requires knowledge of potential risks and side effects that manifest
themselves not only at the macrolevel (in organs and tissues) [138, 140]. For instance, the effect of POM on the
content of histone and heat shock proteins in the blood and liver of rats was investigated upon intramuscular injection
of this compound into the body [143], since the changes, undetectable by means of assessing traditional indicators,
can be identified using other methods. One of the possible mechanisms of the damaging effect of nanoparticles at the
molecular level can be their effect on the tertiary structure of proteins. It may be accompanied by immune reactions
towards denatured proteins that acquire the properties of antigens alien to the body, by increased proteolysis, apoptosis,
necrosis, inflammation, and membrane permeability [144, 145]. Fractions of histone proteins and heat-shock proteins
are informative indicators of changes in cells at an early stage of nanoparticles influence before the appearance of the
“macrotoxicity” signs. The synthesis of inflammatory factors by lymphocytes depends on the modifications and the
amount of histone proteins, the release of which from DNA is essential for the expression of proinflammatory factor
genes [146–148]. The disruption of the structure of various body proteins is counteracted by heat shock proteins
(Hsp), a class of conservative proteins, whose expression increases with the increasing temperature, the action of
toxic substances [150], or under other conditions stressing the cell [149]. Heat shock proteins can act as chaperones,
restoring native conformation in other proteins. They can enhance proteolysis, reduce apoptosis, and participate in
the transport of other proteins and gene expression [149–152]. The liver is the main organ of detoxication, it is
saturated with a large number of specific cells presenting antigens, and it normally deposits iron. Therefore, this
organ was chosen as the object of experimental research. The action of most toxicants leads to liver infiltration by
lymphocytes coming from the blood. The toxic effect of Mo72Fe30 in cases of single and repeated administration
at the cellular, subcellular and organismal levels was studied as regards the content of histone proteins, heat shock
proteins and cytolytic enzymes. The experiment showed no expression of heat shock proteins Hsp70 in the liver cells
of intact animals [153], and the expression of Hsp60 was detected on average in about 30±7 cells per unit area. When
determining the content of histone proteins in blood lymphocytes [143], during all periods of POM load, no significant
changes were found in the fractions of histone proteins, which, according to the literature, regulate the expression of
genes of proinflammatory factors [148, 154]. A study of heat shock proteins [143] has detected no Hsp70 in the
liver in the groups of both intact and control animals, while Hsp60 were recorded. It indicated the inducible nature
of Hsp70 and the constitutive of Hsp60. The normalization of biochemical parameters (characterizing the state of
the liver) within 30 days of POM administration [132, 143], gives evidence for the activation of defense systems in
the organism. Heat shock proteins restore the native conformation of denatured proteins, which can also segregate
proteases, and new proteins are synthesized instead of the segregated ones.
Thus, the single and multiple administration of iron-molybdenum POMs manifested itself at the molecular level
only in changes in the content of heat shock proteins [143] involved in the adaptation and maintenance of homeostasis.
The studies carried out by a number of authors yielded a suggestion that the absence of an increase in heat shock
proteins in response to the action of a stress factor is a violation of adaptation [155, 156]. The action of POM (single
and multiple) did not cause a decrease in the amount of histone proteins in blood lymphocytes, which allows an
assumption about the absence of autoimmune aggression of these cells against liver tissue. An increase in the amount
of Hsp60 and Hsp70 heat shock proteins in rat liver after single and multiple administration of POM can be considered
as a way of adaptation, which is confirmed by a study of indicators of cytolysis and synthetic liver function [157,158].
The content of heat shock proteins in the thymus and spleen was also studied, and it was shown that POM
administration is accompanied by an increase in the number of cells containing Hsp60 and Hsp70 heat shock proteins
in both organs [108, 132, 159]. The increased expression of heat shock proteins in the thymus [160], despite the
presence of a hematothymic barrier, gives reasons to suppose the ability of POM to overcome the histo-hematic
barriers of immune privileged organs [161]. Taking into account the results of the ongoing studies [161], it has been
shown that POM can also exert a similar effect on other organs with special histo-hematic barriers, in particular,
hematoencephalic, hematoophthalmic, hemato-testicular, etc. According to the results of histological studies, the
effect of POM on immune privileged organs did not lead to a change in their morphology and structure. There are
prospects concerning the transport of medicinal substances with the help of POM across the histo-hematic barriers.
In the course of further investigation of the action of POMs at the cellular level, the effect of Mo72Fe30 and
Mo132 on normal and transformed fibroblasts was assessed [162]. The effect of polyoxometalates on cell survival
in culture and their cytotoxic action have been studied [163]. Human dermal fibroblasts (HDF) are more resistant to
Mo72Fe30. On the contrary, Mo132 causes extensive destruction of the membrane organelles of dermal fibroblasts in
the first hours after exposure. Thus, it can be concluded that Mo72Fe30 is not toxic for normal fibroblasts (it causes
only weak changes in cells), while Mo132 is toxic for both normal and transformed fibroblasts, and its damaging effect
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is more pronounced on transformed fibroblasts. A decrease in the proliferative activity of cells (cell multiplication by
division) was recorded. An assessment of the nanocluster toxicity using the MTT test demonstrated a change in the
mitochondrial activity after the impact of Mo132. Probably, this type of nanocluster inhibits cellular respiration and
causes disruption of energy metabolism in cells. According to the obtained data, the effect of polyoxometalates on
cells is selective. The transformed cells accumulated inorganic elements included in the composition of Mo72Fe30
polyoxometalate (e.g., molybdenum) more intensively than of Mo132. At the same time, iron and molybdenum were
absorbed from simpler compounds (iron and molybdenum salts) in smaller amounts, which confirms the selectivity of
the action. For instance, 24 hours after the exposure to Mo72Fe30, the number of transformed cells decreased, and cells
with an uncontoured cell membrane (indicated by an arrow in Fig. 3) and an increased number of microvilli appeared.
This increases the membrane surface, as was recorded by means of optical, electron, and scanning probe microscopy
(a comparison of images obtained by different methods is of interest), and can lead, in turn, to an additional increase
in its ability to interact with drugs. The obtained results confirm the prospects for the application of POMs in the field
of biomedicine, including the use of Mo132 in oncological practice [163].
FIG. 3. Transformed fibroblasts after exposure to Mo72Fe30 POM: a – optical microscopy (×1000
magnification); b – atomic force microscopy; c – scanning electron microscopy (×15550 magnifica-
tion) (equipment of the Ural Center of Shared Use “Modern Nanotechnologies” of the Ural Federal
University). The increase in the number of microvilli is indicated by arrows
3. Association of POMs with bioactive substances and polymers
Polyoxometalates that have been selected in the course of research (Scheme 1) as having characteristics that make
their practical use in biomedicine promising, are studied for the compliance of their properties to requirements to the
materials for targeted drug delivery systems (Scheme 2).
The Keplerate-type POMs and alike, being hydrophilic particles, are able to associate (form conjugates) in their
external sphere with diverse substances, which include surfactants (SAs) of various nature [164–171], dyes, photosen-
sitizers [109, 110, 172–174], and polymers [174–179], mainly water-soluble ones. POMs functionalization makes it
possible to selectively influence their hydrophilic and hydrophobic properties [110], create catalytic and photocatalytic
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systems with adjustable characteristics, as well as compositions for targeted delivery in biomedicine, controlled by an
electric [179] or magnetic field [180,181]. The hydrophobized POMs acquire an ability to more actively interact with
molecules of nonpolar substances and adsorb them [110]. There appears a possibility of formation of ionic associates
based on POM and cations of metals (alkaline earths, rare earths, transition metals, including luminescent labels and
magnetic resonance imaging (MRI) tags [19, 121–123]), and of cationic surfactants. Weaker, e.g., hydrogen, bonds
also actively participate in the interaction of organic compounds with POMs [182]. The formation of POM associates
with water-soluble nonionic polymers [174–179, 183–185], including the biocompatible ones, makes it possible to
create protective shells on the POM surface, similar to polyethylene glycol (PEG) layers, or to diblock copolymers on
nanocapsules [186–194]. In a number of cases, the energy factor (interaction enthalpy) contributes to the formation of
these associates. For instance, the enthalpy of POM and polymer interaction is negative over the entire concentration
range of the components in the Mo72Fe30 – polyvinylpyrrolidone (PVP) system [177]. Similar local concentration
regions were found for the systems containing polyethylene glycol (PEG) and polyvinyl alcohol (PVA) [183]. In some
of the studied systems, the formation of associates is facilitated by the entropy factor [183].
As is noted above, the use of ionic associates of POMs with rare earths as components of diagnostic systems in
biomedicine has been proposed [19, 121–123, 195, 196]. In such associates, POM recharging occurs, so the resulting
complex can be positively charged [197], unlike the initial POM, and be transferred in an electric field by iontophoresis
to the cathode instead of the anode. The structure of a POM is retained in associates [197], which was shown by IR and
Raman spectroscopy. A number of drugs, including antibiotics, form bioactive anions in solutions, the association of
which directly with POM is prevented by the Coulomb repulsion. The competitive interaction of drug cations with the
existing complexing anions also complicates the formation of the cation-POM complexes [197]. On the other hand,
there is a way to obtain transportable associates of anionic bioactive substances with POM, for example, through the
bridging calcium cations [119, 198]. The discovered POM stabilization in associates with calcium will be discussed
below. It is important to note the ability of the Keplerate and compositionally similar toroidal [88–91, 110] POMs to
self-association in solutions, i.e., to self-assembly into hollow single-walled globules (Fig. 4) [91,199], the diameter of
which can vary from tens to hundreds of nanometers, depending on concentration, acidity, and dielectric permittivity
of the medium [199]. These formations can also be considered as transport units for the targeted delivery of medicinal
substances, and the formation of associates, e.g., with surfactants, makes it possible to control the properties of POMs
not only at the level of single molecules, but also at the level of globules and aggregates [111, 180, 181].
In the course of investigations, the ratio of components in the formed POM-polymer associates (Fig. 5) was
established, which in some cases, is close to the calculated value of the monomolecular coating of POM with polymer
chains [175, 178, 184]. Such systems include, for example, associates based on polyvinyl alcohol, PVP with Mo132,
and on PVP with Mo72Fe30. As mentioned above, spontaneous energetically favorable formation of associates occurs
in some systems, e.g., of PVP with Mo72Fe30 (in the entire concentration range of components), as well as in certain
concentration ranges - of polyvinyl alcohol and PEG with Mo72Fe30 [177,183]. The interaction of POM with polymer
macromolecules has specific features, and one of the main ones is the nonlinearity of the associates physicochemical
properties dependence on concentration [175,176,200,201]. The oscillating concentration dependencies (Fig. 6–8) are
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FIG. 4. POM globules, 20000-time magnification. (The electron micrograph was obtained using
the equipment of the Ural Center of Shared Use “Modern Nanotechnologies” of the Ural Federal
University)
associated with the non-statistical nature of the mutual distribution of the interacting nanoscale components [200,201].
They are observed for such independent characteristics as optical density, solution viscosity, electrical properties,
particle size, etc. Obviously, this fact should be taken into account when choosing the ratio of components in associates
used for the targeted drug delivery.
FIG. 5. Diagram of a polymer-salt complex structure [178]
It has been established that Mo72Fe30 POM forms associates with the drugs that are most promising in terms
of targeted delivery. Thiamine chloride (vitamin B1) was considered as a model substance [161, 197]. Thiamine
is present in a solution in the form of cations, which get associated with the POM polyanion. It was confirmed by
UV/Vis spectroscopy, by measuring the pH of solutions, zeta potential, and the size of the particles in them. In
concentrated solutions, colloidal particles get formed along with the solid phase of the resulting conjugates, in which
the preservation of the original POM structure and the presence of thiamine are confirmed. To this end, IR and Raman
spectroscopy were used. The thiamine-POM ratio in the associates was estimated as 4:1, with the retention of the total
negative charge of the conjugate. Mo72Fe30 associates with substances belonging to the class of immunomodulators,
e.g., with 2-morpholino-5-phenyl-6H-1,3,4-thiadiazine bromide [197–202].
Mo72Fe30 forms conjugates with such an antibiotic as kanamycin sulfate, without reducing the activity of this
drug when affecting colibacilli cultures [197]. Also, it was possible to establish that Mo72Fe30 can associate with
insulin in aqueous solutions [197], as well as with amphiphilic protein molecules, such as albumins [161, 197]. This
result is of great importance in terms of the possibility of obtaining complexes with POM and with homing peptides for
the implementation of bioactive substances targeted delivery to specific cells. Protein molecules, the so-called protein
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FIG. 6. Dependence of the solutions dynamic viscosity (η) [201] on the ratio of the
polyvinylpyrrolidone macromolecular units number per 1 ion of Mo132 polyoxometalate (1); 2 –
viscosity of the specified POM aqueous solution; the dotted line indicates the viscosity of a 1% pure
polymer aqueous solution. ©Pleiades Publishing, Ltd. 2015
FIG. 7. Optical density (A) (λ = 450 nm) [201] of Mo132 POM and polymer solutions, depending
on the molar ratios of the components: a – of polyvinylpyrrolidone (CPOM = 1.5·10−6 mol/L); b –
of polyvinyl alcohol (CPOM = 1.5·10−7 mol/L). ©Pleiades Publishing, Ltd. 2015
FIG. 8. Concentration dependencies of the dielectric loss factor [175] at the 25 Hz frequency for the
PVA-based composites, including (1) Mo132, (2) Mo138, and (3) Mo72Fe30. C is the POM content
(wt %). ©Pleiades Publishing, Ltd. 2016
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corona, significantly influence the biological properties of nanoparticles [203–207]. It should be noted that the blood
serum proteins stabilize Mo72Fe30 [161,177], in spite of the fact that the serum is an alkaline medium, where the POM
is unstable, in principle, which is illustrated by its rapid decomposition in buffer solutions. Stabilization by the natural
protein corona opens up prospects for the prolonged action of the POM-based drugs. While in buffer solutions with the
corresponding pH 8 Mo72Fe30 decomposes rapidly, and the effective constant of the POM destruction rate has a value
of 2.6·10−2 h−1 even for the self-aggregated ones, its value is only 1.8·10−3 h−1 in the composition of conjugates
with proteins [96]. The initial experiments aimed at establishing the possibility of obtaining conjugates of Mo72Fe30
with doxorubicine yielded positive results. Doxorubicin is an anthracycline antitumor antibiotic [208–212] that is
actively used in medicine in the treatment of various types of solid tumors. Two main mechanisms of doxorubicin’s
antitumor activity are proposed in the literature, namely DNA intercalation and disruption of the viral DNA repair, and
the generation of free radicals that damage the cell membrane, DNA, and proteins [213]. Along with high efficiency,
doxorubicin has high toxicity associated with low selectivity for its action. In addition to high cardiotoxicity, a decrease
in bone marrow activity (myelosuppression) is often observed in the course of doxorubicin administration [214]. To
date, a significant amount of research has been conducted with the purpose of reducing the toxic effect of doxorubicin
on healthy cells by creating means of its targeted delivery. Various types of different systems for the targeted delivery
have been considered, in particular, based on liposomes [215–222] (similar forms have already found application
in medical practice [223–227]); proteins [228–233]; polymers [234–243]; fullerenes and CNT [35, 244–251]; metal
and oxide nanoparticles [52, 76] (gold [250–255], silver [255], and iron oxide [256–260]). The further study of the
properties of POM-doxorubicin conjugates should be recognized as promising, given the corresponding properties of
POM.
An important aspect of the possible use of POM in the field of biomedicine is the possibility of iontophoretic,
including percutaneous, transport of Keplerates and their conjugates into the body. These processes were considered
in our previous work [179]. As is noted above, these processes are important, in particular, for the delivery of drugs,
e.g., of doxorubicin, to the regions with a low degree of vascularization.
Additional opportunities for the use of Mo72Fe30 in biomedicine are opened by the preparation of its new coordi-
nation compound [261] that can serve as a transportable donor of nitric oxide – a mediator of some important processes
in the body [262–267], which include the activation of antiviral and antimicrobial activity, and the cardiotropic action.
It is important that the compound [POM-(NO2)x] (NO2)y (where x = 6, y = 14 ± 3), obtained by the interaction of
nitrogen oxides with POM and characterized by a complex of methods, belongs to the group of water-soluble com-
pounds. Iron compounds are used as nitric oxide donor and transport vehicles for its delivery [268–275]. Examples of
obtaining other POMs containing nitric oxide can be found in the literature [276–278].
4. POMs desrtuction process and their stabilization
One of the main above-mentioned properties of POMs is their ability to degrade in diluted solutions [279], which
depends on both the POM initial concentration and the pH of the medium. This property can be useful for POM
removal from the body after the function of bioactive substances delivery has been performed. The results of studies of
thermal stability and destruction of the Keplerate and toroidal type POMs in the solid state using spectroscopic methods
are given in [280–286]. At the same time, it was shown that a thorough spectroscopic analysis and a comprehensive
interpretation of the results are necessary [280, 286] in order to avoid unreliable conclusions [284] about the POMs’
thermal stability. The features of the processes of POMs destruction in solutions have been considered in the earlier
performed works [135, 198]. For each of the considered POM, there is a region of stable state in aqueous solutions in
terms of POM concentration and medium pH. For Mo132, this region can be clearly illustrated by a diagram (Fig. 9).
The region of Mo72Fe30 stability in sufficiently concentrated solutions is also limited by pH within the 3.7–5.9 range
[100, 106]. Under the conditions that exist beyond the range of POM stability, they undergo gradual destruction into
simpler components.
UV/Vis spectroscopy was used for studying the kinetics of POM degradation in solution. The time dependen-
cies (τ ) of the optical density A (directly proportional to the current POM concentration) obtained [135] for different
initial concentrations of Mo72Fe30 POM were approximated by equations describing reactions of different orders, in
order to establish which of them the experimental data obey. A satisfactory agreement with the linear dependence was





= f(τ) coordinates for Mo72Fe30 solutions in the domain of relatively low concentrations.
The experimental data correlated best with the first order reaction equation. For relatively high Mo72Fe30 concentra-
tions, the experimental data were approximated by two lines with different slopes (for different time periods). Each of





= f(τ) coordinates. In this case, the constant of POM decomposition rate in the
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FIG. 9. Hypothetical diagram of Mo132 POM stability [184]. ©Pleiades Publishing, Ltd. 2010
first time interval coincided with the constant of Mo72Fe30 destruction rate in low concentration solutions. Such a sit-
uation can be explained by a change in the mechanism of the destruction process depending on the concentration and
a change in the limiting stage of the general process where inflection between two lines was observed. An example of
the experimental data processing is shown in Fig. 10. For comparison, the table also shows the data on the destruction
kinetics for a toroid-structured Mo138 POM, for which the one-step destruction process in a solution with a relatively
high (2.4·10−6 mol/L) initial POM concentration was satisfactorily described by the first-order reaction equation.
FIG. 10. Kinetics of the Mo72Fe30 Keplerate decomposition [135] in a solution with the initial
concentration of 5·10−6 M. ©Pleiades Publishing, Ltd. 2015
In [135], a supposition was made concerning the possible differences in the process of Mo72Fe30 POM destruction
at different concentrations. The mentioned POMs tend to form aggregates or hollow globules in solutions [89,199,286–
292]. In solutions with high concentrations, aggregation proceeds in such a way that a significant part of the available
POM molecules (ions) happens to be bound into aggregates within a relatively short time. In diluted solutions, the
relative amount of free POM molecules is more noticeable. Therefore, it can be assumed that the free POM destruction
rate constant is higher than that of those bound into globules, in which they are protected due to the presence of bonds
between molecules (ions) and a lesser contact with the environment. When the experimental dependencies demonstrate
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an inflection within the same initial concentration, a change in the limiting stage occurs, apparently, after the majority
of the available free POM molecules have been spent.
The proposed hypothesis is supported by the fact that the constant of the aggregates formation rate [289] (calcu-
lated also for the first-order reaction) is lower than the POM decomposition rate constant, and equals 5.4–7·10−5 h−1
for Mo72Fe30, in particular. Therefore, the initially obtained solution should contain at the first stage a sufficiently
large number of unbound POM molecules, which decompose faster than the aggregated ones. A relatively faster pro-
cess of decomposition of free Mo72Fe30 molecules, which are initially present in a significant amount, can also explain
a steeper initial section in the kinetic dependencies of aggregate formation [289]. The rate constant in this section can
be estimated as 2.5–3.9·10−4 h−1. In this case, it can be assumed that the appearance of iron ions due to the POM
destruction leads to acceleration of the aggregation process. The literature indicates a similar effect of cations on the
formation of aggregates [291]. At the same time, the existence of singlet POMs in a solution is not typical for the
toroid-like Mo138 [286]; therefore, its destruction is a one-step process in a certain time interval.
In [289], the ratio between the number of aggregates and singlet nanoclusters was determined, from which the
degree of aggregation was calculated. The authors apparently did not take into account a possibility of this ratio
increase due to a higher rate of Mo72Fe30 POM free ions destruction, as well as the change of the total concentration
of POM, which could lead to an overestimation of the globule formation rate constant.
Another question that arises is about the mechanism of POM decomposition s included in the aggregates. Do
the POM molecules get destroyed directly in the globules, and then the latter disintegrate, or does the preliminary
disintegration of the globules occur when the concentration of free POM ions decreases? The destruction of POM in
globules could have possibly led to a change in their size; however, according to the data from [289], the size of the
existing globules remains practically unchanged. Therefore, it can be assumed that the destruction of POM molecules
(ions) into simpler compounds occurs after the preliminary destruction of these globules, which goes along with the
decreasing concentration of the studied POM in the course of its decomposition in the solution. Some previously
found differences in the kinetics of Mo138 POM and Mo72Fe30 destruction can be associated with both the globules
destruction rate, and with the stability of the polyoxometalates themselves. Thus, it was shown in [135] that, depending
on the concentration of Mo72Fe30 POM solutions, the disintegration of single nanoclusters, or the “dissolution” of the
existing globules consisting of nanoclusters, can be the limiting stage of the overall destruction process.
The destruction of Mo132 has also been investigated [198]. An analysis of the spectrophotometric data from
experiments on the destruction of Mo132 POM showed that the time dependencies of the optical density and, accord-
ingly, of the POM concentration, have an induction period when the concentration decreases rather slowly. Then the
decomposition accelerates, and after passing the interval with the maximum rate, it noticeably slows down again. For
this reason, the standard linearization of the data using kinetic reaction equations of various orders (including those at
the stages after the induction period) was a failure. Considering the shape of the obtained dependences, it was logical
to assume that the destruction proceeds in the autocatalytic reaction mode. A typical picture of the kinetic dependence
is shown in Fig. 11a.
The experimental kinetic data obtained at the initial concentration of the studied POM of 10−5 mol/L, were
processed using an equation that describes the autocatalytic process [293–295]:
C=C0(K0+KcC0)/(KcC0+K0 exp((K0+KcC0)t),
where C0 is the nanocluster initial concentration, K0 is the non-catalytic process rate constant, Kc is the catalytic
process rate constant, C is the nanocluster current concentration, and t is the time. The values of K0 were estimated
from the slope of the dependence during the induction period, and it was assumed that the catalytic process rate
is negligible during this period (of the non-catalytic reaction), which is a standard assumption in such cases. The
experimental data for the interval, corresponding to the rapid course of the catalytic process with further deceleration
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FIG. 11. Typical kinetic dependencies (concentration - time) of the Mo132 destruction process [198]
at an initial concentration of 7·10−6 mol/L (a) with an induction period; shape of dependence with
no induction period (b) at the introduction of sodium molybdate (the initial Mo132 concentration:
5·10−6 mol/L). ©Pleiades Publishing, Ltd. 2016
due to the consumption of autocatalytic particles, were used for determining Kc values for each experimental point,
and then plotting the time dependence of this parameter.
It is impossible to deduce the Kc value from the above equation by using the analytical method, therefore a special
algorithm was developed for determining this value. It consists in the following:
1. Since the equation is transcendental, it was rewritten as:
C(KcC0+K0 exp((K0+KcC0)t)- C0(K0+KcC0)=0 or F(C,t, Kc)=0.
2. The available data array C=C(t) was used to construct the function F=F(C, t, Kc), according to which, the
time-dependent Kc values were reconstructed.
The performed calculations showed that the value of the catalytic process rate constant practically did not change
in the corresponding interval in time and averaged about 4.8·102 L/mol/min at the initial POM concentration of
10−5 mol/L, and 6·102 L/mol/min at 5·10−6 mol/L, respectively. The half-transformation time estimated on the
basis of such rate constant values, correlates well with the experimental data (about 4-5 hours). Thus, it can be consid-
ered that the destruction process proceeds as an autocatalytic reaction, and the used assumptions are correct, since the
shape of kinetic dependence could be approximated successfully by a corresponding equation. The possible reasons
for the differences in the obtained Kc values at different initial concentrations will be discussed below. The value of
K0 in this case was about 1.8·10−3 min−1, regardless of the initial POM concentration in the range of 1-10 µM.
The features of Mo132 destruction in the presence of calcium ions, associated with the POM polyanion, are also
considered. The hydrated calcium ions are capable of forming differently configured associates with POMs [119].
Calcium can stabilize POM in solutions, thus increasing the effective value of its lifetime in solutions. In this case,
as in that of POM association with polymers, the non-additive properties are observed, for instance, the nonlinear
concentration-dependent ability of calcium to stabilize POM. In the processes of calcium cations and POM interaction,
apparently, 20 pores in the Keplerate structure are involved as active centers, i.e., the places where the association of
the hydrated ions of divalent metals occurs [296]. It cannot be excluded that the filling of these positions leads to the
associate’s stabilization. In addition, the next level of interactions is realized along with the increase in the associated
ions concentration. Naturally, ion associates are found in dynamic equilibrium with free ions in a solution, and a certain
excess of associated ions is required to ensure the filling of active positions. The change in time of the solutions optical
density at the POM characteristic wavelength indicated that the almost completely destroyed pure Mo132 persisted for
several days in the presence of calcium, especially at the Ca-POM ratios of 8:1, 24:1, and 60:1. The presence of POM
with the original structure was confirmed by Raman spectroscopy.
This is another case when the POM destruction process is described as an autocatalytic reaction. Such parameters
as the induction period duration, and the rate constants in this interval and during the catalytic process were determined
for the destruction reaction. When the Ca content increases, the induction period lengthens, and the rate constant of the
noncatalytic stage decreases (Fig. 12), but nonmonotonically depends on the Ca content in solutions, and has minima
for some compositions. The autocatalytic process rate constant increased along with an increase in the Ca content. It
Physicochemical and biochemical properties of the Keplerate-type nanocluster... 95
FIG. 12. Dependencies of the induction period duration (a), K0 (b), and Kc (c) on the Ca2+-POM
ratio for solutions with the initial Mo132 concentration of 10−5 mol/L [198]. ©Pleiades Publishing,
Ltd. 2016
should be noted that since the formation of variously structured POM-Ca associates is possible, the rate constants can
really differ, as the mechanism of POM destruction is determined by its structure.
It was noted during the research that the pH of freshly prepared POM solutions decreased depending on the amount
of Ca (Fig. 13) at POM concentrations of 1 and 10 µM, and the nature of the kinetic parameters dependence (in absolute
value) on the Ca concentration was generally similar to the pH concentration curve, although the pure Mo132 solution
did not fit this series. On the one hand, this shows that the destruction mechanism and rate are determined not only by
the solution pH. Along with that, it can be stated that the maximum stability of some compositions is determined by a
combination of a sufficiently long induction period and a relatively low non-catalytic stage rate constant.
When considering the pure Mo132 destruction process again, a monotonic decrease in the pH of solutions was
observed at a concentration of 10 µM. Notable is that this decrease was more rapid during the induction period. From
the point of view of the direction of change in acidity, this regularity is quite logical taking into account the possible
simultaneous process of the available pentavalent molybdenum oxidation with atmospheric oxygen, which can be









Due to the presence of the above-described change in acidity, the hydroxonium ions H3O+ were considered as
autocatalytic particles, which is often the case. However, it was taken into account that along with the decreasing
pH of calcium-containing solutions and increasing amount of Ca2+ in them, the rate constant of the non-catalytic
stage of the process decreases, and its duration increases. Therefore, non-condensed molybdate (or dimolybdate) ions
that appear during the destruction of Mo132, can act as the autocatalytic particles. Further onIn addition, the diagram
from [184] (Fig. 9) was taken into account, as it showed the regions of stability of various molybdate forms (including
Mo132 ions) depending on the total molybdenum in solutions, and on the pH of the medium. The point corresponding
to a POM solution with initial concentration of 10 µM in a more detailed fragment of the diagram (Fig. 14), is found in
the region of heptamolybdate ions stable existence. It should be noted that the earlier studies of POM decomposition
by photon correlation spectroscopy [184] discovered the appearance of POM particles with an effective size of about
1.3 nm, which is close to the estimated size of the heptamolybdate ion. If, in addition, fragments containing less than
7 molybdenum atoms also appear during the POM destruction, then they must be completed up to a heptamolybdate
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FIG. 13. Dependencies of the Mo132 solutions pH on the calcium-POM ratio (a) at the concen-
tration of 10−6 mol/L, as well as on the experimental time at concentrations of 10−5 (b) and
10−6 mol/L (c) [198]. ©Pleiades Publishing, Ltd. 2016
form that is stable in this region. Then, it cannot be ruled out that these particles “attack” a POM to obtain the required
material. An accelerated destruction in this case is achieved when weakly condensed compounds or monomolybdate
forms get accumulated in the solution. The slowing down of the destruction process corresponds to the consumption
of the mentioned autocatalytic particles. At the initial Mo132 concentration of 1 µM, the resulting monomolybdate
particles do not need to build up to heptamolybdate.
FIG. 14. Fragment of the phase diagram of forms of ions in a solution: A - heptamolybdate ions
stability region; B - monomolybdate existence region. The arrows indicate the direction of change
in the acidity of the solution during the Mo132 destruction [198]. ©Pleiades Publishing, Ltd. 2016
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The conclusions made above about the nature of autocatalytic particles are consistent with the data on increase
in POMs stability in acidic buffer solutions [279]. These data indirectly indicate that hydronium ions do not catalyze
destruction. The catalytic action of monomolybdate ions can be confirmed by a direct experiment. The addition of
sodium molybdate into the Mo132 solution (with the initial concentration of 5 µM) practically did not affect the pH
of the solution, and led to the exclusion of the induction stage from the destruction process (Fig. 11b). In this case,
the molar content of molybdenum in the form of monomolybdate was set equal to the molar content of molybdenum
contained in the form of Mo132. Changes in the solutions acidity during the destruction of more diluted (e.g., µM)
Mo132 solutions without additives did not have a monotonic character (Fig. 11). It is also related to the thermody-
namic factor (diagram in Fig. 14). The point corresponding to the indicated concentration is found in another region
of the diagram, where simpler ions are stable. However, the pH decreases in the course of destruction, and the com-
position transits across the boundary between two regions (Fig. 14). At the initial Mo132 concentration of µM, the
appearing monomolybdate particles do not need to build up to heptamolybdate before crossing the boundary of the
indicated regions. Such a flow of processes is even more complicated than in the first case, so it becomes difficult to
unambiguously interpret the kinetics and describe it by the used autocatalytic equation. The course of reaction can be
additionally complicated by the fact that products of destruction, including pentavalent molybdenum, have different
degree of stability in different regions of phase diagram. They have a higher stability [200] in the condensed forms in
region A (Fig. 14). As for the Keplerate structures destruction, it was noted that the Keplerate decomposition stage
(with the solution turning blue) [104] can be followed by the Mo(V) compounds oxidation, accompanied by discol-
oration. The change in the medium acidity during POM destruction in the presence of Ca2+ is also not monotonic
in all cases. However, the above-noted general trend of an increase in the induction period duration along with an
increase in the amount of Ca2+ in the solution, may be associated with the fact that calcium ions are able to form suf-
ficiently stable associates with molybdate, which leads to at least partial binding of autocatalytic particles. However,
calcium molybdate (CaMoO4) solubility product was not obtained at the studied concentrations of solutions, and no
precipitation in noticeable amounts was observed. To summarize, let us note once again that POM destruction is a
process, the rate of which is determined by both POM concentration and medium acidity. The destruction mechanism
can vary depending on these conditions. There are possibilities for temporal stabilization of POMs and a decrease in
the value of the process rate constant – by regulating either the acidity of the medium and POM self-aggregation, or
POM interaction with stabilizing agents, including those of natural origin.
The effect of light on POM solutions increases the rate of their destruction [297, 298] and can change the mech-
anism of this process (to be discussed in more detail in the next section). Mutual stabilization of POMs and water-
soluble nonionic polymers (including biocompatible ones) during the formation of their associates, which manifested
itself under sufficiently severe photothermal effect on systems, was studied in [198, 297–299]. This aspect is impor-
tant not only in itself, but also when using POM as, e.g., part of ointment compositions, or sterilized materials. The
stabilization effect was studied by means of the EPR spectroscopy for determining the number of paramagnetic cen-
ters (spins) as an indicator of the composition components destruction processes. Quite interesting are the results of
studies, which indicate the above-noted significant stabilization of Mo72Fe30 POM due to the interaction with proteins
of the blood serum [161, 300], which has an alkaline pH. In buffer solutions with a similar pH, POM destruction pro-
ceeded at a very high rate, while in the serum they persisted for up to dozens of hours. The destruction rate constant
of POM in the resulting conjugates with serum proteins was at least an order of magnitude lower than in aqueous
solutions of the POM itself. Thus, there exists a possibility to regulate POMs stability, their lifetime, and the period of
the conjugated drugs release. Preliminary stabilization of POM in solutions can be carried out outside the body.
5. Prospects for the creation of POM-based releasing systems with feedback
An integrated approach to the study of the physicochemical properties of the Mo132 and Mo72Fe30 Keplerate
POMs [138, 161, 301], as well as the possibility of their association with bioactive molecules and fluorescent dyes,
made it possible to formulate the concepts [302–304] of creating long-time-drug-releasing systems (LDRS) with a
function LDRS will be based on the release of molecules of bioactive (medicinal) substances, initially bound with
POM, and the intensification of fluorescent labels luminescence. The release occurs at the normal pH (7.2-7.4) of
the body environment, due to the POM destruction. The main principle LDRS are based on is the discovered effect
[302–304] of a fluorescent label (xanthene dye rhodamine-B, RhB) inactivation on the POM surface due to charge
transfer processes. This makes it possible to monitor the drugs release due to the intensification of the signal from
the fluorescent labels [305, 306] incorported in the applied LDRS. In [307], it was found that RhB, chosen from a
number of xanthene dyes, is characterized by the concentration quenching of luminescence due to a static mechanism,
i.e., formation of non-luminescent H-aggregates. It was shown in [304] that the reason for the RhB fluorescence
quenching in an associate with POM is the photoinduced charge transfer from the level of the lowest unoccupied
molecular orbital (LUMO) of the donor (RhB) to the LUMO level of the acceptor (POM). According to the cyclic
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voltammetry data [308,309], the LUMO level of RhB is 0.65 eV higher than the LUMO level of POM, which leads to
the spontaneous electron transfer from RhB to POM in an excited state and formation of the RhB+/Mon−132 ionic pair.
It should be noted that the transfer of electrons between the HOMO/LUMO levels of dye molecules and POM
(Fig. 15) also underlies the promising use of such photosensitized systems in catalysis [310]. The experiments per-
formed to date have yielded such components of the above systems (Fig. 16) as the NHS ester of rhodamine-B - a
potential fluorescent label [302, 303], which can be covalently fixed on the macromolecular backbone of biocompati-
ble polymers (chitosan, polyallylamine) by an amide bond. It was shown that the Mo132 nanocluster, which had been
chosen as a model POM, can be connected with matrix macromolecules of biocompatible polymers, such as polyal-
lylamines, aminopropyltrimethoxysilane, and chitosan, resulting in microgels based on similar matrices. In principle,
the proposed LDRS can be used as a subcutaneous implant with the function of on-line pharmacokinetic monitoring.
Such nanoscale systems can, in principle, be created on the basis of hybrid supramolecular assemblies that act au-
tonomously, like liposomes with highly specific ligands on their surface [311]. Such systems can also be components
of a microscopic implant [312] or of a biocompatible polymer matrix capable of carrying a large number of bioactive
molecules (BAM) for the long-time release [313, 314]. As regards the future, the further steps under consideration
relate to both realization of the target properties of the proposed LDRS systems [302], and to optimization of their
chemical design, and in vitro and in vivo study of their biological properties. Such a task can be solved, for instance,
by studying a possibility of pairwise assembly of components of a composition that includes a polymer, a POM, a
xanthene dye (rhodamine) covalently bound in the form of NHS-ester, and a drug.
FIG. 15. Photochemical processes in a POM-dye system on the example of a toroidal compound
Mo138
FIG. 16. Diagram of a promising POM-based releasing system. BAM - bioactive molecules; GLUA
- glutaric dialdehyde
The oscillatory nature of the dependence of the physicochemical characteristics of POM-based associates (Sec-
tion 3) and the possibility of influencing the compositions by ultraviolet radiation have been pointed out above. It
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is important to understand the light-influenced behavior of nanostructured objects when developing photoinduced
controlled-release systems (Section 1.1) and feedback systems (Section 5). It is impossible to miss the fact that in
some cases, oscillatory phenomena are observed during the impact on the systems that contain gradually destructing
POMs, [297,303]. In this case, fluctuations depend not only on the composition; temporal oscillations of fundamental
physical and chemical properties, such as optical density, photovoltaic potential, etc. also occur. Oscillations of phys-
ical properties are most often characteristic of the systems containing macromolecular components, e.g., polymers or
POMs [175, 201, 315]. For POMs, the oscillatory phenomena prerequisites include the large size of polyanions, as
well as the nonlinearity of characteristics, including the optical properties [316] of molybdenum-containing complexes
(associates) with organic substances, e.g., with citric acid [317]. Due to the reversibility of redox reactions of d-metal
ions (electron transfer in associates [297]), POMs are able to participate in oscillatory processes. The oscillatory phe-
nomena mechanism can have significant differences in the differently composed systems and in varying conditions
in which these phenomena are observed. Each case requires a detailed consideration, which we did below for the
above-described systems containing Mo132, rhodamine-B, and also showing signs of properties oscillation.
The experiments aimed at studying Mo132 destruction in aqueous solutions with a concentration of 5.4 µM and
in contact with argon showed that this process is stimulated by the influence of light [303]. For irradiation, two LEDs
were used together, the first of which emitted light mainly at 630 and 570 nm wavelengths, and the second at 466 nm.
This combination made it possible to reproduce the main spectral components of daylight. Before irradiation of the
solutions, they were preliminarily purged with argon. In the course of the experiments (Fig. 17), there was a general
decrease in the optical density (A) at 455 nm wavelength, associated with POM destruction, and the measured value A
was found to fluctuate exceeding the measurement error. The previously performed experiments [318] demonstrated
similar oscillations related to the potential difference U between the frontally UV-irradiated Mo132 solution, which also
contained polyvinyl alcohol (PVA), and a likewise solution, though light-protected (Fig. 18). The potential difference
had a negative value and increased with time. It occurred due to a decrease in the Mo(V) concentration in the irradiated
solution during the photochemical destruction of POM, and the oxidation to Mo(VI) during Mo132 destruction despite
the presence of PVA. On the contrary, when other POMs were present in solutions instead of Mo132, partial reduction
of molybdenum ions occurred during the interaction with PVA and was accompanied by an increase in positive values
of the potential difference. The presence of a photoinduced potential difference accompanying the photochromic effect
manifestation in molybdenum-containing systems, as well as signs of nonlinear and oscillatory processes, are also
described in [317,319]. Oscillatory processes could occur in this case due to the partial reversibility of photochemical
processes.
FIG. 17. Relative optical density of Mo132 solutions as a function of the irradiation time (min) in
contact with argon (1) and air (2). The initial optical density is designated as 1
It should be noted that, in contrast to the systems containing, e.g., ammonium heptamolybdate, where redox
reactions are reversible [297] and the occurrence of fluctuations in the potential difference is generally understandable,
Mo132 destruction proceeds irreversibly [198]. The products of destruction do not absorb light intensely at the 455 nm
wavelength characteristic of Mo132. In this relation, there arises a question about the causes of the fluctuating optical
density of Mo132 solutions and of the concentration-induced potential difference. If the value of U could fluctuate due
to a reversible change in the content of Mo(V), including its non-Keplerate forms, upon their interaction with PVA,
then why did the optical density fluctuate? Note that the LEDs irradiated the studied solutions from above [303], i.e.,
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FIG. 18. Potential difference (∆V) between the illuminated and light-protected Mo132 solution
(0.015 wt. %) - PVA (10 wt. %) [318]. ©Pleiades Publishing, Ltd. 2009
from where the gaseous medium was in contact with the solutions. In this case, the harder part of the LEDs radiation at
466 nm was absorbed by the solution itself, the characteristic wavelength of which is in the near region. Therefore, it
can be assumed that the photoinitiated reaction of Mo132 destruction, accompanied by the oxidation of molybdenum to
Mo(VI), was localized precisely at the solution surface in a relatively thin layer, the thickness of which did not exceed
0.5 mm [320]. In this case, the described above potential difference appeared between the liquid-gas interface and
bulk solution. So, the solution surface can be considered formally as a positive electrode (cathode). The reaction of
POM oxidative destruction, which occurs due to the interaction with residual oxygen in argon (no more than 1 vol.%),









O2 + 4H+ + 4e⇒ 2H2O.








The oxidation-reduction potentials of the components of the considered system make the above reaction feasible.
At least for the second half-reaction, the standard potential is +1.229 V.
During Mo132 decomposition in accordance with the proposed reaction scheme, the acidity of the medium is sup-
posed to increase, which was confirmed experimentally [198]. The potential difference between the solution surface
layer and its lower part should accelerate the migration of protons (hydronium ions H3O+) deeper into the solution and
the supply of anions to the cathode. Taking into account the circumstance that the spectrophotometer beam aperture
did not cover the entire measuring cell and the beam was passing through its middle part, it can be assumed that the
relative increase in optical density in the observed oscillations was associated with an increase in the Mo132 concen-
tration in the aperture due to the accelerated diffusion from the lower part of the cell. The diffusion coefficients of
hydronium ions and polyanions are sufficiently different; therefore, an oppositely directed diffusion potential could
occur in the system under study, which, on the contrary, slowed down the flow of ions, thus leading to a stepwise
decrease in the value of A (Fig. 17), since POM destruction continued. The interaction of these factors could lead to
the observed fluctuations.
Another factor that could potentially lead to a temporary partial blocking of the reaction of POM destruction is the
oxygen deficiency in the solution, because the rate of oxygen dissolution in a liquid medium is limited. The value of D,
the coefficient of oxygen diffusion in an aqueous medium given in [320], is around 2·10−5 cm2/s. A comparison of this
value with the effective D value of Mo132 polyanions under electrodiffusion conditions (1.8·10−7 cm2/s) [107] (POM
concentration of 4·10−4 mol/L), shows that the latter are much less mobile. For this reason, the supply of polyanions
to the solution surface is more likely the limiting stage of the oxidative photodecomposition process. In this case, the
diffusion restrictions, as well as fluctuations of A values, can at least be partially removed due to intensive vertical
mixing of the solution. However, this is difficult to implement with the used measurement scheme. On the other
hand, in order to obtain additional information, it is possible to increase the oxygen content in the medium contacting
the solution, as it was done in the next experiment (Fig. 17) by replacing argon with air. With an increase in the
oxygen content in the gaseous medium, the process of POM destruction accelerated in general, but the optical density
fluctuations did not disappear, which indirectly confirms the hypothesized mechanism of the occurrence of oscillations
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of A. In addition, attention should be paid to the amount of oxygen required in accordance with the reaction scheme
for the oxidation of Mo132 in the solution: it takes about 1.5·10−6 g of oxygen per 1 ml of a solution in the used
concentration. The solubility of oxygen at room temperature in water and diluted solutions is about 6.6·10−3 g/L. If
1 ml of the initial solution could contain about 6.6·10−6 g of dissolved oxygen, then its amount was about 4.4 times
higher than that required for POM oxidation.
The photochemical nature of POM oxidative destruction can be confirmed by the stabilization of Mo132 upon
formation of its associates with rhodamine-B, a dye of the xanthene series [303] (the main absorption maximum at a
wavelength of 558 nm, near one of the maxima of the used LED). Stabilization manifests itself, for instance, during
irradiation of such solutions (Mo132 - RhB molar ratio of 1:8) in contact with air (Fig. 19). In another case, when
a substance that is more easily oxidized than POM is in contact with the above associates, the Mo132-rhodamine-B
system is capable of playing the role of a photoactivated catalyst. The oxidation of compounds such as toluene and
isopropyl alcohol proceeds under quite mild conditions. Toluene is selectively oxidized to benzyl alcohol and ben-
zaldehyde [321], and isopropyl alcohol is oxidized to acetone. Photoactivated compounds of the nanocluster type,
including d-metals in different oxidation states, can be practically useful as catalysts for the oxidation of organic
compounds [322, 323], for instance in processes of organic synthesis, and of alternative energetics (hydrogen produc-
tion) for reducing the potential of electrochemical decomposition of aqueous solutions [324]. Examples of the use of
molybdenum and tungsten compounds in the photolysis of water [316, 325] are known from the literature.
FIG. 19. Relative optical density of the irradiated solutions of Mo132 (1) and Mo132 – rhodamin-
B (2) in contact with air (as a function of time, in min)
So, it has been shown that diffusion processes can be the cause of the oscillatory phenomena occurrence, in
particular, of oscillations of the measured optical density of Mo132 POM aqueous solutions under local exposure to
light. In the studied system, the processes of POM oxidative photodestruction occurring in the surface part of the
solution, are limited by the mobility of Mo132 polyanions, the speed of which periodically changes depending on
the ratio of the values of the concentration and diffusion potentials arising between the surface of the solution and
its deep part. Further studies of oscillatory phenomena involving POM are of interest, especially taking into account
the possibility of using these compounds in catalysis. It should be assumed that similar phenomena can occur in the
body’s environment, and it should be taken into account, in particular, when monitoring drug release.
6. Conclusion
Thus, there are a number of factors that make it possible to consider molybdenum-based nanocluster POMs as
compounds for use in biomedicine which show promise. These physical and biochemical properties include: the ability
of POMs to undergo decomposition in vivo; the absence of accumulation of POM and their components in organs and
tissues due to elimination in the course of natural metabolism; the possibility of obtaining conjugates of drugs and
bioactive substances (including protein), biocompatible polymers, indicator dyes; targeted transport (for instance,
ionophoresis) of POM and their conjugates into the body. Mo72Fe30 is able to penetrate into immuno-privileged
organs (e.g., brain, eyes, thymus, spleen, etc.) and overcome blood-tissue barriers. At the same time, Mo72Fe30 has
low toxicity for warm-blooded organisms; its administration by various methods does not lead to disruption of organs
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and systems, being reflected only in small reversible changes at the metabolic level, e.g., in the aminotransferase
activity. In addition, it was noted that the organism of animals (rats) is capable of adapting to the influence of POM,
which, among other things, provides the normalization of the above-mentioned parameter. The effect of Mo72Fe30 at
the molecular level revealed itself only in a change in the content of heat shock proteins, which are involved in the
adaptation of the organism and maintenance of homeostasis. The single and multiple action of POM did not cause
a decrease in the amount of histone proteins in blood lymphocytes, which makes a suggestion about the absence of
autoimmune aggression of these cells against liver tissue. The effect of rapid recovery of the hemoglobin level and
the number of erythrocytes was established upon administration of Mo72Fe30 preparations to animals in a state of
post-hemorrhagic anemia. It indicates the possibility of therapeutic use for POMs, which have a positive effect on the
processes of erythropoiesis.
Mo132, which contains Mo(V), is more toxic than Mo72Fe30, in general. A study of the effect of these two POMs
on cell cultures of normal and transformed fibroblasts showed that Mo72Fe30 is practically non-toxic for normal
fibroblasts, while Mo132 is toxic for both normal and transformed fibroblasts, and its damaging effect on transformed
fibroblasts is stronger: a decrease in cell proliferative activity and an accelerated differentiation of transformed rat
fibroblasts were recorded. The experimental results indicate the potential use of Mo132 in chemotherapy.
It is important to study the aspects related to the processes of POM destruction under various conditions in their
free and conjugated states, as it allows predicting the lifetime of POM-based functional transport units and regulating
their stability. The studies have shown possible mechanisms of POM destruction, including photoinitiated ones, and
established that stabilizing factors can include self-aggregation of POM into hollow globular associates, the interaction
of POM with such biogenic ions as calcium, and association with water-soluble nonionic biocompatible polymers. One
of the most important stabilizing factors influencing POM upon entering normal alkaline environments of the body
(e.g., blood) is the interaction with proteins, in particular, with albumins (protein corona appearance), while in the
environment of a corresponding alkaline buffer solution, POMs decompose much more quckly.
Fundamental approaches for the creation of new POM-based controlled releasing systems with feedback have
been proposed. In these systems, POM conjugates with a drug and an indicator luminescent dye are initially bound
with a matrix of a biocompatible polymeric organic or inorganic carrier in the microgel composition. This should
ensure prolonged release of drugs and simultaneous monitoring of their residual concentration indicated by the fluo-
rescent signal of the dye molecules.
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[277] Müller A., Krickemeyer E., Dillinger S., Bögge H., Plass W., Proust A., Dloczik L., Menke C., Meyer J., Rohlf-
ing R. New Perspectives in Polyoxometalate Chemistry by Isolation of Compound Containing Very Large Moieties
as Transferable Building Blocks: (NMe4)5[As2Mo8V4AsO40]·3H2O, (NH4)21[H3Mo57V6(NO)6O183(H2O)18]·65H2O,
(NH2Me2)18(NH4)6[Mo57V6(NO)6O183(H2O)18]·14H2O and (NH4)12[Mo36(NO)4O108(H2O)16]·33H2O. Z. anorg. allg. Chem.,
1994, 620, P. 599–619.
[278] Müller A., Krickemeyer E., et al. [Mo−154(NO)14O420(OH)28(H2O)70](25±5)−: A Water-Soluble Big Wheel with More than 700 Atoms
and a Relative Molecular Mass of About 24 000. Angew. Chem. Int. Ed. Engl., 1995, 34(19), P. 2122–2124.
[279] Matsumoto T., Nakamura I., Ishiguro K., Tsunashima R. Concentration Dependent Stability of Fullerene-Shaped Metal-Oxide Nanocluster
{Mo132} in Aqueous Solution. Sci. Adv. Mat., 2014, 6, P. 1–5.
[280] Grzhegorzhevskii K.V., Zelenovskiy P.S., Koryakova O.V., Ostroushko A.A. Thermal destruction of giant polyoxometalate nanoclusters: a
vibrational spectroscopy study. Inorg. Chim. Acta, 2019, 489, P. 287–300.
[281] Ostroushko A.A., Tonkushina M.O., et al. Study of the stability of solid polyoxometalate Mo72Fe30 with a buckyball structure. Russ. J.
Inorg. Chem., 2012, 57(6), P. 858–863.
[282] Ostroushko A.A., Tonkushina M.O., Safronov A.P., Men’shikov S.Yu., Korotaev V.Yu. Thermal Behavior of Polyoxometalate Mo132. Russ.
J. Inorg. Chem., 2009, 54(2), P. 172–179.
[283] Ostroushko A.A., Sennikov M.Yu. Polythermal Study of Electrophysical Characteristics of Poly(vinyl alcohol) Polymer-Salt Films. Russ. J.
Inorg. Chem., 2009, 54(1), P. 115–120.
[284] Bielan’ski A., Małecka-Luban’ska A., Micek-Ilnicka A., Müller A., Diemann E. Thermal properties of
(NH4)32[Mo138O416H6(H2O)58(CH3COO)6]·approximately 250H2O: on the route to prove the complexity of a nanostructured
landscape-especially with different type of H2O ligands-embedded in an ’ocean’ of water molecules. Inorg. Chim. Acta, 2002, 338, P. 7–12.
[285] Bielan’ski A., Małecka-Luban’ska A., Micek-Ilnicka A., Diemann E. Thermal stability of giant wheel type polyoxomolybdates and their
derivatives. J. Molec. Struct., 2006, 365, P. 55–65.
[286] Ostroushko A.A., Korotayev V.Yu., Tonkushina M.O., Grzhegorzhevskii K., Vazhenin V.A., Kutyashev I.B., Martynova N.A., Men’shikov
S.Yu., Selezneva N.V. Electrotransport, Sorption, and Photochemical Properties of Nanocluster Polyoxomolibdates with a Toroidal Structure.
Russ. J. Phys. Chem. A, 2012, 86(8), P. 1268–1273.
[287] Müller A., Diemann E., Kuhlmann Ch., Eimer W., Serain C., Tak T., Knochel A., Pranzas P.K. Hierarchic patterning: architectures beyond
’giant molecular wheels’. Chem. Commun., 2001, 19, P. 1928–1929.
[288] Kistler M.L., Liu T., Gouzerh P., Todea A.-M., Müller A. Molybdenum-oxide based unique polyprotic nanoacids showing different deproto-
nations and related assembly processes in solution. Dalton Trans., 2009, 26, P. 5094–5100.
[289] Liu T. An Unusually Slow Self-Assembly of Giant Inorganic Ions in Aqueous Solution, J. Am. Chem. Soc., 2003, 125, P. 312–313.
[290] Liu T. Surfactant-Induced Trans-Interface Transportation and Complex Formation of Giant Polyoxomolybdate Clusters, J. Clust. Sci. (Achim
Müller Issue), 2003, 14, P. 215–226.
[291] Liu, G., Liu T. Thermodynamic properties of the unique self-assembly of Mo72Fe30 inorganic macro-ions in salt-free and salt-containing
aqueous solutions. Langmuir, 2005, 21(7), P. 2713–2720.
112 A. A. Ostroushko, K. V. Grzhegorzhevskii, S. Yu. Medvedeva, et al.
[292] Zhang J., Li D., Liu G., Glover K.J., Liu T. Lag Periods during the Self-Assembly of Mo(72)Fe(30) Macroions: Connection to the Virus
Capsid Formation Process. J. Am. Chem. Soc., 2009, 131, P. 15152–15159.
[293] Steinfeld J.I., Francisco J.S., Hase W.L. Chemical Kinetics and Dynamics, 2nd Edition., Prentice Hall. 1998, 409 pp.
[294] Stanciu I. Mechanism of autocatalytic reactions. Publisher Lap Lambert Academic Publishing. 2014, 64 pp.
[295] Ramirez W.F. Computational Methods in Process Simulation. 2nd edit. Butterworth-Heinemann. Oxford. 1997, 512 pp.
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